What is BioSensics?
Founded in 2007 by three Harvard scientists, BioSensics has dedicated over 17 years to the research and development of advanced digital health technologies and validated biomarkers. The company specializes in wearable sensors for clinical trials, patient monitoring, and health assessment, with a particular focus on neurological and rare disorders. BioSensics' innovative approach to robust digital health data collection and precise disease symptom measurement has positioned it as a global leader in integrating wearable technology into healthcare and clinical research.
How much funding has BioSensics raised?
BioSensics has raised a total of $2.9M across 2 funding rounds:
Grant
$2.5M
Debt
$350K
Grant (2017): $2.5M with participation from National Institutes of Health
Debt (2020): $350K led by PPP
Key Investors in BioSensics
National Institutes of Health
The National Institutes of Health (NIH), founded in 1887 and based in Bethesda, Maryland, is an agency of the United States Department of Health and Human Services and is the primary agency of the United States government responsible for biomedical and health-related research.
PPP
Public-Private Partnership
What's next for BioSensics?
The recent major strategic investment in BioSensics signals a pivotal phase for the company, likely aimed at scaling its operations, expanding its product portfolio, and further penetrating the clinical trials and patient monitoring markets. This capital infusion is expected to accelerate the development and validation of new biomarkers and digital health solutions, reinforcing BioSensics' leadership in addressing complex neurological and rare disease challenges through cutting-edge wearable technology.
See full BioSensics company page
